[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
| Symbol | RPTOR |
| Full Name | Regulatory Associated Protein of MTOR Complex 1 (Raptor) |
| Chromosome |
17q25.3 |
| NCBI Gene |
57521 |
| Ensembl |
ENSG00000141564 |
| OMIM |
607592 |
| UniProt |
Q8N122 |
| Protein |
[Raptor Protein](/proteins/rptor-protein) |
| Diseases |
[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Huntington's Disease](/diseases/huntingtons), [ALS](/diseases/als), Tuberous Sclerosis |
| Expression |
[Hippocampus](/brain-regions/hippocampus), [Cortex](/brain-regions/cortex), Cerebellum, Substantia nigra (ubiquitous) |
| mTORC1 signaling, [autophagy](/entities/autophagy) regulation, protein synthesis, lysosomal biogenesis, AMPK crosstalk |
RPTOR (Regulatory Associated Protein of MTOR Complex 1), also known as Raptor, is an essential scaffolding component of the mTOR Complex 1 (mTORC1), located on chromosome 17q25.3. Raptor functions as a substrate-recognition subunit that recruits downstream targets to mTORC1 for phosphorylation, thereby controlling protein synthesis, autophagy, lysosomal biogenesis, and cellular metabolism. As the defining component that distinguishes mTORC1 from mTORC2 (which uses RICTOR), Raptor is a critical determinant of mTORC1 substrate specificity.
mTORC1 hyperactivation through Raptor-dependent signaling is one of the most consistently observed pathological features across neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Aberrant mTORC1 activation suppresses autophagy, leading to accumulation of misfolded proteins and damaged organelles — hallmarks of virtually all neurodegenerative conditions.
The RPTOR gene spans approximately 260 kb on chromosome 17q25.3 and contains 30 exons. It encodes a 1,335-amino acid protein (Raptor) that is highly conserved across eukaryotes. The gene produces several splice variants, though the full-length isoform is predominant in neural tissue.
- TFEB binding sites: Lysosomal stress induces RPTOR transcription through a TFEB-dependent feedback loop
- FOXO response elements: Nutrient deprivation increases RPTOR expression via FOXO transcription factors
- AMPK regulation: AMPK directly phosphorylates Raptor at S722/S792 to inhibit mTORC1 during energy stress
- Insulin/IGF1 signaling: Growth factor receptor activation promotes Raptor-mTOR assembly through PI3K-AKT-TSC pathway
Raptor is indispensable for mTORC1 function, serving as the scaffold that assembles the complex and recruits substrates:
graph TD
AmTOR["AmTOR kinase"] --- B["Raptor (RPTOR)"]
A--- C["mLST8"]
A--- D["DEPTOR"]
A--- E["PRAS40"]
B -->|"Recruits via TOS motif"| F["S6K1/S6K2"]
B -->|"Recruits via TOS motif"| G["4E-BP1/4E-BP2"]
B -->|"Recognizes"| H["ULK1 complex"]
B -->|"Recognizes"| I["TFEB"]
J["Amino acids / Growth factors"] -->|"Activate"| A
K["AMPK / Energy stress"] -->|"Phosphorylate S722/S792"| B
K -->|"Inhibit"| A
-
Protein synthesis control: Raptor-dependent mTORC1 activation phosphorylates S6K1 and 4E-BP1, driving cap-dependent translation of synaptic proteins, growth factors, and metabolic enzymes critical for neuronal function and synaptic plasticity.
-
Autophagy regulation: mTORC1-Raptor phosphorylates and inhibits ULK1/ULK2 autophagy-initiating kinase and TFEB transcription factor. When mTORC1 is active, autophagy is suppressed; when nutrients are scarce or rapamycin inhibits the complex, autophagy is induced. This is the primary mechanism by which mTOR controls protein aggregate clearance in neurons.
-
Lysosomal biogenesis: Raptor-mTORC1 phosphorylates TFEB at S211, causing cytoplasmic retention by 14-3-3 proteins. Inhibiting mTORC1 allows TFEB nuclear translocation and activation of lysosomal and autophagy gene networks — a promising therapeutic strategy for neurodegeneration.
-
Synaptic plasticity: mTORC1-dependent local translation at synapses is required for long-term potentiation (LTP) and long-term depression (LTD). Raptor knockdown in hippocampal neurons impairs both LTP maintenance and memory consolidation.
-
Mitochondrial metabolism: Raptor-mTORC1 regulates PGC-1α and mitochondrial biogenesis programs, influencing neuronal energy metabolism and oxidative stress resilience.
-
Axonal growth and regeneration: mTORC1-Raptor signaling through S6K drives axonal protein synthesis required for growth cone dynamics and regeneration after injury.
mTORC1 hyperactivation through Raptor is a consistent finding in AD:
- Autophagy impairment: Elevated mTORC1 activity in AD hippocampus suppresses autophagy, allowing accumulation of amyloid-β and hyperphosphorylated tau. Raptor phosphorylation status shows that mTORC1 is constitutively active in AD neurons.
- Tau phosphorylation: mTORC1-S6K directly phosphorylates tau at multiple sites. Raptor-dependent S6K activation contributes to neurofibrillary tangle formation independently of GSK3β and CDK5.
- Aβ production: mTORC1 activation increases BACE1 translation and amyloidogenic APP processing. Rapamycin treatment reduces Aβ levels in transgenic AD mouse models.
- Insulin resistance: Brain insulin resistance in AD disrupts the insulin-PI3K-AKT-mTORC1 axis, paradoxically leading to mTORC1 hyperactivation through loss of feedback inhibition.
- Rapamycin as therapeutic: Rapamycin and rapalogs (which dissociate Raptor from mTOR) show neuroprotective effects in multiple AD models by restoring autophagy and reducing Aβ and tau pathology.
- α-Synuclein clearance: mTORC1 hyperactivation through Raptor impairs autophagic clearance of α-synuclein aggregates. Rapamycin treatment enhances α-synuclein degradation through autophagy induction.
- Dopaminergic neuron vulnerability: Substantia nigra dopaminergic neurons show elevated mTORC1-Raptor activity in PD, which suppresses mitophagy through ULK1 inhibition, exacerbating mitochondrial dysfunction.
- LRRK2 interaction: LRRK2 G2019S mutation activates mTORC1-Raptor signaling, contributing to impaired autophagy in familial PD.
- PINK1/Parkin connection: Loss of PINK1 or Parkin leads to compensatory mTORC1 activation, further suppressing the mitophagy that is already compromised.
- Polyglutamine aggregates: mTORC1 inhibition with rapamycin enhances clearance of mutant huntingtin aggregates, one of the first demonstrations that mTOR-autophagy modulation could be therapeutic for neurodegeneration.
- Striatal vulnerability: Medium spiny neurons in the striatum show high basal mTORC1-Raptor activity, potentially explaining their selective vulnerability when autophagy is further impaired by mutant HTT.
- TDP-43 and FUS aggregates: mTORC1 hyperactivation accelerates TDP-43 and FUS aggregate accumulation. Rapamycin treatment promotes their autophagic clearance.
- C9orf72 repeat expansion: C9orf72 loss-of-function disrupts mTORC1-Raptor regulation, contributing to autophagy-lysosome dysfunction in ALS/FTD.
Raptor is ubiquitously expressed with particularly high levels in metabolically active tissues:
- Hippocampus: Strong expression in CA1, CA3, and dentate gyrus, consistent with roles in synaptic plasticity and memory
- Cortex: Expressed across all layers with enrichment in deep-layer pyramidal neurons
- Cerebellum: High expression in Purkinje cells
- Substantia nigra: Expressed in dopaminergic neurons
- Developing brain: Highest expression during periods of rapid neuronal growth and synaptogenesis
- Glial cells: Moderate expression in astrocytes and oligodendrocytes; lower in resting microglia
- Rapamycin and rapalogs: Rapamycin (sirolimus) and its analogs (everolimus, temsirolimus) allosterically inhibit mTORC1 by disrupting Raptor-mTOR interaction through FKBP12. Clinical trials are underway for AD and other neurodegenerative diseases.
- ATP-competitive mTOR inhibitors: Torin1, Torin2, and INK128 inhibit both mTORC1 and mTORC2 but provide more complete mTORC1 inhibition than rapalogs.
- AMPK activators: Metformin, AICAR, and other AMPK activators phosphorylate Raptor at S722/S792, inhibiting mTORC1 and inducing autophagy. Metformin is being investigated for AD prevention.
- Caloric restriction: Dietary restriction inhibits mTORC1-Raptor signaling and enhances autophagy, showing neuroprotective effects across multiple disease models.
A key therapeutic challenge is selectively inhibiting mTORC1 (through Raptor) while preserving mTORC2 (through RICTOR) signaling, as mTORC2 promotes neuronal survival through AKT phosphorylation. Raptor-specific degraders and selective mTORC1 allosteric modulators are under development.